[ad_1]
Nexus CEO Mariam Darsot cuts the ribbon during Friday’s opening ceremony for the pharmaceutical plant in Highlands Corporate Park. Present for the event were US Representative Bryan Steil, Pleasant Prairie Village President John Steinbrink, State Representative Samantha Kerkman, CEO of Wisconsin Economic Development Corp. Missy Hughes and Governor Tony Evers.
Village of Pleasant Prairie photo
For Kenosha News
PLEASANT PRAIRIE – Governor Tony Evers and U.S. Representative Brian Steil were among those in attendance on Friday to celebrate the grand opening of Nexus Pharmaceuticals’ new manufacturing facility in Pleasant Prairie.
Nexus Pharmaceuticals is a privately owned, female-owned pharmaceutical company based in Lincolnshire, Ill. That produces specialty and generic injectable drugs for use by hospitals in the United States. The Pleasant Prairie Manufacturing Plant at 10300 128th Ave. will support the production and supply of drugs in a range of therapeutic areas, including anesthesia, oncology, cardiovascular disease and neurology.
“Not only is Nexus Pharmaceuticals committed to innovation, quality and safety, the company also provides good family support jobs that are essential to the sustainability of our state’s economy. â€Said Evers. “Southeastern Wisconsin is increasingly becoming a destination of choice for high value-added manufacturing jobs that require a skilled and educated workforce, and this project is a testament to Wisconsin’s lead in manufacturing cutting edge and our work to link the points of vocational training to transport infrastructure. “
“We are proud to call Wisconsin the new home for our company’s first manufacturing facility,†said Mariam Darsot, CEO of Nexus. “This investment is necessary to stimulate the continued growth of the US pharmaceutical industry. There is an increasing patient demand for high quality and affordable generic injections. The addition of our Wisconsin plant will allow Nexus to produce a more stable and reliable supply of sterile injectables, a category particularly sensitive to drug shortages.
[ad_2]
